Table 6 Liposomal vaccine formulations tested in parasitic infection models
From: Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Lipid(s) and sterol used | Parasite | Cell line/animal model used | Administration route | Promising liposome formulation | References |
|---|---|---|---|---|---|
MPL/QS21 (liposome-based) | Plasmodium falciparum | Rhesus macaques | Intramuscular | MPL/QS21 (liposome-based) | [114] |
Egg lecithin/Chol, egg lecithin/SA and egg lecithin/PA | Leishmania donovani | BALB/c mice | Intraperitoneal | Lecithin/Chol/SA | [116] |
PC/Chol, PC/SA, PC/PA and PC/PS | L. donovani | – | Intravenous, N/A | PC/SA | |
EPC/EPG, EPC/EPG/Chol and DSPC/DPPG/Chol | P. vinckei | Female C57BL/6J mice | Intraperitoneal | EPC/EPG, EPC/EPG/Chol and DSPC/DPPG/Chol | [113] |